Utilization and outcomes of the 21-gene recurrence score in de novo metastatic breast cancer
SP Yang, K Liu, Y Li, GQ Li, JY Li, YY Lin… - Expert Review of …, 2024 - Taylor & Francis
Background Limited data exist regarding the utility and validity of the 21-gene recurrence
score (RS) in patients with de novo metastatic breast cancer (dnMBC). This study aimed to …
score (RS) in patients with de novo metastatic breast cancer (dnMBC). This study aimed to …
Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer
Y Zhou, H Wang, J Yang, F Wang, D Dong… - Journal of …, 2024 - Taylor & Francis
This study aimed to compare the efficacy of pyrotinib, trastuzumab combined with
chemotherapy with different lines therapy in human epidermal growth factor receptor 2 …
chemotherapy with different lines therapy in human epidermal growth factor receptor 2 …